Search

Your search keyword '"Chiriboga, Claudia A"' showing total 324 results

Search Constraints

Start Over You searched for: Author "Chiriboga, Claudia A" Remove constraint Author: "Chiriboga, Claudia A"
324 results on '"Chiriboga, Claudia A"'

Search Results

2. Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

5. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.

7. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial

8. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

9. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

10. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

11. Natural history of infantile-onset spinal muscular atrophy.

12. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

15. Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy

16. Delphi Consensus Panel on Assessing Clinically Meaningful Treatment Outcomes in Adults Living with Spinal Muscular Atrophy (SMA) (P2-11.007)

17. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study.

19. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

20. Muscle-specific SMN reduction reveals motor neuron-independent disease in spinal muscular atrophy models

24. JEWELFISH: 24-month Safety, Pharmacodynamic and Exploratory Efficacy Data in Non-Treatment-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (P7-9.004)

25. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function

26. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

27. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

29. Contributors

31. Newborn Screening for Spinal Muscular Atrophy in New York State

32. Onasemnogene Abeparvovec for Presymptomatic Infants with Spinal Muscular Atrophy and Two Copies of SMN2 (S39.004)

33. Onasemnogene Abeparvovec in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with Three Copies of SMN2 (P15-5.001)

34. JEWELFISH: Safety, Pharmacodynamic and Exploratory Efficacy Data in Non-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (P15-5.004)

35. Pooled Safety Data from the Risdiplam Clinical Trial Development Program (P18-5.001)

36. Bulbar function in spinal muscular atrophy (SMA): State of art and new challenges. 21st July 2023, Rome, Italy

37. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

44. Psychometric properties of the PEDI-CAT for children and youth with spinal muscular atrophy

46. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study

47. Improving Care and Empowering Adults Living with SMA:A Call to Action in the New Treatment Era

49. Onasemnogene Abeparvovec Gene Therapy in Presymptomatic Spinal Muscular Atrophy (SMA): SPR1NT Study Update in Children with 3 Copies of SMN2 (4163)

50. JEWELFISH: Safety and Pharmacodynamic Data in Non-Naïve Patients with Spinal Muscular Atrophy (SMA) Receiving Treatment with Risdiplam (2316)

Catalog

Books, media, physical & digital resources